Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor
DOI:
https://doi.org/10.23938/ASSN.0859Keywords:
Hypertriglyceridemia. Everolimus. Acute pancreatitis. Lipid-lowering therapy.Abstract
Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events.
We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively.
Downloads
References
ROSENSON RS. Hypertriglyceridemia. UpToDate. Ültima actualización: 9 de marzo de 2020.
LEW S, CHAMBERLAIN RS. Risk of metabolic complications in patients with solid tumors treated with mTOR inhibitors: meta-analysis. Anticancer Res 2016; 36: 1711-1718.
U.S. Food & Drugs Administration. Everolimus (Afinitor). https://www.fda.gov/drugs/resources-information-approved-drugs/everolimus-afinitor
SIVENDRAN S, AGARWAL N, GARTRELL B, YING J, BOUCHER KM, CHOUEIRI TK et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev 2014; 40: 190-196 http://dx.doi.org/10.1016/j.ctrv.2013.04.005
NASHAN B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845-1857. https://doi.org/10.1517/13543784.11.12.1845
U.S. National Cancer Institute. Cancer treatment: Everolimus. https://www.cancer.gov/about-cancer/treatment/drugs/everolimus
MOTZER RJ, ESCUDIER B, OUDARD S, HUTSON TE, PORTA C, BRACARDA S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. https://doi.org/10.1016/s0140-6736(08)61039-9
HOOGEVEEN RC, BALLANTYNE CM, POWNALL HJ, OPEKUN AR, HACHEY DL, JAFFE JS et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72: 1244-1250. https://doi.org/10.1097/00007890-200110150-00011
TSUANG W, NAVANEETHAN U, RUIZ L, PALASCAK JB, GELRUD A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol 2009; 104: 984-991. https://doi.org/10.1038/ajg.2009.27
CELIK S, DOESCH A, ERBEL C, BLESSING E, AMMON K, KOCH A et al. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 2008; 86: 245-250. https://doi.org/10.1097/tp.0b013e318177281e
BUSAIDY NL, FAROOKI A, DOWLATI A, PERENTESIS JP, DANCEY JE, DOYLE LA et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012; 30: 2919-2928. https://doi.org/10.1200/jco.2011.39.7356
SUBRAMANIAM S, ZELL JA, KUNZ PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. J Natl Compr Canc Netw 2013: 5-9. https://doi.org/10.6004/jnccn.2013.0003
DE GENNARO COLONNA V, PAVANELLO C, RUSCONI F, SARTORE-BIANCHI A, SIENA S, CASTELNUOVO S et al. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). J Clin Pharm Ther 2018; 43: 114-116. https://doi.org/10.1111/jcpt.12588
ACHARYA GK, HITA AG, YEUNG SJ, YEUNG SJ. Diabetic ketoacidosis and acute pancreatitis: serious adverse effects of everolimus. Ann Emerg Med 2017; 69: 666-667. https://doi.org/10.1016/j.annemergmed.2017.01.002
SARI M, EKENEL M. Everolimus-induced severe hypertriglyceridemia and acute pancreatitis in a patient with tuberous sclerosis. Am J Ther 2019; 26: e558-e559. https://doi.org/10.1097/mjt.0000000000000821
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
